Monthly newsletter: Read the latest issue
Learn more about our degree programs and admission requirements
Find the information you need to conduct your research and academic studies
See KCU's beautiful campus
See faculty research interests
KCU-COM alumni enjoy free CME in conjunction with Homecoming
KANSAS CITY, Mo. (July 16, 2013) – Kansas City University of Medicine and Biosciences (KCU) announced today the appointment of Stanley C. McDermott, Pharm.D., MS, as the director of the KCU Center for Community and Clinical Research, effective July 29. Jeffrey N. Joyce, PhD, vice president for research at KCU, said McDermott is the best possible choice to direct the operations of the Center for Community and Clinical Research, which will provide core resources and a home for programs in community health, pediatric health, and human physiology. “His experience in business and pharmaceutical development, inter-institutional collaborations, clinical research and community-based health improvement make him an ideal leader for KCU,” Joyce said.McDermott brings 30 years of experience in clinical trial research. He comes to KCU from Austen BioInnovation Institute in Akron (ABIA) in Akron, Ohio, where he served as vice president and head for the Center for Clinical Trials and Product Development. ABIA represents a collaboration of local health-care institutions, universities and funding organizations with a primary focus on accelerating the translation of clinical ideas to commercialized products, simulated educational opportunities and community health improvement initiatives.McDermott’s career began in Kansas City as a pharmacist for what is now North Kansas City Hospital. He transitioned to pharmaceutical development and clinical trial research, beginning as a clinical research associate for Marion Laboratories, Inc. Here his management responsibilities increased to leading and managing successively larger research and development efforts including global clinical trials to augment, manage and support clinical investigational drug and device trials for a series of pharmaceutical and contract research organization (CRO) companies.
He holds doctoral and bachelor of science degrees in pharmacy and a master of science in pharmacology from the University of Missouri–Kansas City. He is currently a member of the UMKC Pharmacy Foundation Board of Directors.
“I look forward to joining the KCU team, Dr. Joyce and many colleagues as we identify ways to significantly enhance clinical research and community involvement in the KCU and greater-Kansas City regions,” McDermott said. “It will be great to be back in Kansas City, as well.”KCUMB’s Center for Community and Clinical Research includes the Dybedal Clinical Research Center, the first adult not-for-profit academic clinical trial facility in Kansas City, Mo. It is accredited by the Federal Drug Administration to participate in each of the four phases of pharmaceutical drug studies. Each phase concentrates on a specific purpose and stage of drug development, beginning with treatment in a small group to evaluate a drug’s safety and concluding with post-marketing studies to delineate a treatment’s risks, benefits and optimal use.About KCUMBKansas City University of Medicine and Biosciences, founded in 1916, is a fully accredited, private university, with a College of Biosciences and a College of Osteopathic Medicine. The College of Osteopathic Medicine is the oldest medical school in Kansas City, Mo., and the largest in the state. It is the second-largest provider of physicians within the state of Missouri, with 72 percent practicing in a primary care specialty and 40 percent in rural areas.
1750 Independence AvenueKansas City, Mo. 64106-14531-800-234-4847 | 816-654-7000